Pipeline Accelerator outcomes

Search and sort the table below for details on projects supported by TIA’s Pipeline Accelerator scheme.

TIA voucher outcomes

Pipeline Accelerator Program	Lead applicant	Affiliation	Project title	Capability provider
2017-18	Dr Christopher J Burns	Metabloq Pty Ltd	High Throughput Screening of Compound Libraries against a Novel Cancer Metabolism Drug Target	ACRF Drug Discovery Centre for Childhood Cancer
2017-18	Dr Glen Carter	Peter Doherty Institute/ BioCurate	Development of Novel Gut-Targeted Antibiotics for the Treatment of Multidrug-Resistant Pathogens	Australian Translational Medicinal Chemistry Facility
2017-18	Prof. Spencer Williams	University of Melbourne	Pharmacokinetics and distribution of novel non-steroidal asthma drugs	Centre for Drug Candidate Optimisation
2017-18	Dr Guy Krippner	Baker IDI	Novel Receptor Agonists for difficult to treat chronic illness	Centre for Drug Candidate Optimisation and Australian Translational Medicinal Chemistry Facility
2017-18	Dr Susie Nilson	CSIRO	Toxicology and pharmacokinetic profiling of a stem cell mobilisation agent	Centre for Drug Candidate Optimisation and TetraQ
2017-18	Dr Natalie Borg	Monash University	A broad-spectrum antiviral target and anticancer target	Compounds Australia
2017-18	Prof. Charles Mackay	Monash University	Developing an agonistic antibody	Monash Antibody Technologies Facility
2017-18	Prof. Rajiv Khanna	QIMR Berghofer	The establishment of a repository of in vitro-expanded T cells for the treatment of viral complications in transplant recipients	Q-Gen Cell Therapies
2019-20 (Core facilities)	Dr David Elliott	Murdoch Children’s Research Institute	Identifying compounds that protect against anthracycline induced heart damage	Australian Translational Medicinal Chemistry Facility
2019-20 (Core facilities)	Prof Tom Gonda	University of South Australia	Development of a small molecule inhibitor of the MYB oncogene as a therapeutic for Acute Myeloid Leukaemia	Australian Translational Medicinal Chemistry Facility
2019-20 (Core facilities)	Dr Steven Petratos	Monash University	Development of Small Molecules to Promote Remyelination in Multiple Sclerosis	Australian Translational Medicinal Chemistry Facility
2019-20 (Core facilities)	Mr Gregory Santamaria	Cyclotek (Aus) Pty Ltd	Development of advanced and novel radioligands for Positron Emission Tomography (PET) imaging	Australian Translational Medicinal Chemistry Facility
2019-20 (Core facilities)	Prof Katherine Andrews	Griffith Institute for Drug Discovery (GRIDD)	Pre-clinical optimisation studies on a new antimalarial drug lead	Centre for Drug Candidate Optimisation
2019-20 (Core facilities)	Dr Ebony Fietz	Gertrude Biomedical Pty Ltd	Preclinical ADME and PK drug properties of novel inhibitors of SOX18 transcription factor	Centre for Drug Candidate Optimisation
2019-20 (Core facilities)	Dr Wim Meutermans	Vast Bioscience Pty Ltd	ADME and PK evaluation of VAST preclinical candidates for postsurgical pain	Centre for Drug Candidate Optimisation
2019-20 (Core facilities)	Prof Bernard Flynn	Monash University	Targeting Sphingosine Kinase 1 for the Treatment of Pulmonary Hypertension	Centre for Drug Candidate Optimisation and TetraQ
2019-20 (Core facilities)	Dr Nicholas Veldhuis	Monash University	Assessing efficacy of analgesic nanoparticles in chemotherapy-induced neuropathic pain	Centre for Integrated Preclinical Drug Development
2019-20 (Core facilities)	A/Prof Brendon Coventry	Cancuravax Pty Ltd	Melanoma Cancer Vaccine Immunotherapy Production & Scaling for Commercialisation	National Biologics Facility NSW Node
2019-20 (Core facilities)	Dr Brad Walsh	GlyTherix Ltd	Production and Lead Selection of Humanised Anti-Glypican-1 Antibodies	National Biologics Facility NSW Node
2019-20 (Core facilities)	Kevin Isch	NeuClone Pty Ltd	Development and validation of an ECL immunoassay method for quantitation of ustekinumab concentration in human serum	TetraQ
2019-20 (Screening)	Prof Brian Gabrielli	TRI	Screen for new agents to selectively kill a novel defect in melanomas	ACRF Drug Discovery Centre
2019-20 (Screening)	Dr Joseph Brock	ANU	Development of an engineered thermal shift assay for the high-throughput discovery of integral membrane protein lead compounds	ANU Centre for Therapeutic Discovery
2019-20 (Screening)	Dr Amee George	ANU	Identifying therapeutics for the treatment of Myelodysplastic Syndrome	ANU Centre for Therapeutic Discovery
2019-20 (Screening)	Prof Si Ming Man	ANU	Novel antitoxin compound discovery for the treatment of antibiotic resistant bacteria	ANU Centre for Therapeutic Discovery
2019-20 (Screening)	Dr Nicholas Eyre	University of Adelaide	Development of inhibitors of dengue virus (DENV) NS1 protein dimerization as novel antiviral therapeutics	Cell Screen SA
2019-20 (Screening)	Dr Benjamin Blasco	GARDP	The discovery and development of novel antibiotics against MDR and XDR Gram-negative pathogens	CO-ADD
2019-20 (Screening)	Ms Natasa Broit	QIMR Berghofer	Identification of novel therapies for the treatment of acral lentiginous melanoma	Griffith Discovery Biology
2019-20 (Screening)	Dr Brian Dymock	UniQuest	Identification of Inhibitors of a key oncogenic protein by Fragment Screening	Monash Fragment Platform
2019-20 (Screening)	Dr Dane Cheasley	Peter MacCallum Cancer Institute	High throughput investigation of synergistic drug combinations for patients with low-grade serous ovarian carcinoma	Victorian Centre for Functional Genomics
2019-20 (Screening)	Dr Nicholas Clemons	Peter MacCallum Cancer Institute	A specific inhibitor of SLC7A11 (XCT) for single agent or combination treatment of cancers with mutant p53	Victorian Centre for Functional Genomics
2019-20 (Screening)	Dr Kathleen Pishas	Peter MacCallum Cancer Institute	Defining the role of clonal interaction in high grade serous ovarian cancer drug resistance	Victorian Centre for Functional Genomics
2019-20 (Screening)	Dr Michael Sharp	St. Vincent’s Institute of Medical Research	Inhibiting the Fanconi Anaemia pathway to target BRCA1/2 negative breast and ovarian cancers	Victorian Centre for Functional Genomics
2020-21 (Round 1 - Screening)	Prof. Ian Street	Children's Cancer Institute	Development of a high-throughput screening assay for a novel activated kinase ALPK1	ACRF Drug Discovery Centre
2020-21 (Round 1 - Screening)	A/Prof Marco Casarotto	Australian National University	Developing therapeutics that treat/prevent ischemia reperfusion injury (IRI)	ANU Centre for Therapeutic Discovery
2020-21 (Round 1 - Screening)	Assoc. Prof. Leonie Quinn	Australian National University	High-Throughput 3D Cell and Organism Screening for new brain cancer (glioma) treatments	ANU Centre for Therapeutic Discovery
2020-21 (Round 1 - Screening)	Prof. Sally-Ann Poulsen	Griffith University	Restoring the efficacy of chemotherapy in drug resistant cancers	Discovery Biology
2020-21 (Round 1 - Screening)	Prof. Murray Whitelaw	University of Adelaide	Discovery and development of new antimicrobials to combat antibiotic resistance	GRIDD Mass Spectrometry Screening Platform
2020-21 (Round 1 - Screening)	Dr Shom Goel	Peter MacCallum Cancer Centre	Improving outcomes for breast cancer patients receiving CDK4/6 inhibitors	Victorian Centre for Functional Genomics
2020-21 (Round 1 - Screening)	Dr. Eleanor Saunders	University of Melbourne	Targeting human leishmaniasis	Victorian Centre for Functional Genomics
2020-21 (Round 1)	Dr Mark Del Borgo	Monash University	Synthesis of novel peptide mimics for use as anti-fibrotic agents	Australian Translational Medicinal Chemistry Facility
2020-21 (Round 1)	Prof. Ian Smyth	Monash University	Inhibiting cystogenesis in Polycystic Kidney Disease with AURKA PROTACs	Australian Translational Medicinal Chemistry Facility
2020-21 (Round 1)	Dr. Christopher Burns	MycRx Pty Ltd	Novel, small-molecule therapeutics for the treatment of cancers addicted to the oncoprotein Myc	Centre for Drug Candidate Optimisation
2020-21 (Round 1)	Prof. Alastair Stewart	Tianli Biotech Pty Ltd	Development of casein kinase 1 delta inhibitors for inflammation, fibrosis and fibrotic cancers	Centre for Drug Candidate Optimisation
2020-21 (Round 1)	Dr. Fernando S. F. Guimaraes	University of Queensland	Development of new anti-breast cancer antibodies for natural killer (NK) cell-based immunotherapy	National Biologics Facility Queensland Node
2020-21 (Round 1)	Prof. John Hooper	Mater Research Institute	Production and Stability Study of 5 variants of 10D7 antibody	National Biologics Facility Queensland Node
2020-21 (Round 1)	Prof. Alex Loukas	James Cook University	Innovative IBD biologics inspired by host-parasite coevolution	National Biologics Facility Queensland Node
2020-21 (Round 1)	Prof. Peter Timms	University of Sunshine Coast	Development of a chlamydial vaccine for koalas: Production of chlamydial proteins at high quality suitable for vaccine trials	National Biologics Facility Victoria Node
2020-21 (Round 1)	Dr. Brad Walsh	Glytherix Ltd	Optimisation and Characterisation of Miltuximab-DFO Bioconjugation	National Biologics Facility Victoria Node
2020-21 (Round 1)	Prof. Andrew Prowse	University of Queensland	Pilot scale GMP production of cardiomyocytes derived from human pluripotent stem cells	Q-Gen Cell Therapeutics
2020-21 (Round 1)	Dr Stuart Fraser	University of Sydney	Nanions: a rapid, non-toxic nanoparticle vaccine platform	TetraQ
2020-21 (Round 1)	Prof. Suddha Rao	QIMR Berghofer Medical Research Institute	Safety and pharmacokinetics study of a novel anti-PD-L1 therapeutic to improve immunotherapy in triple-negative breast cancer	TetraQ
2020-21 (Round 1)	Prof. Mark von Itzstein	Griffith University	Preclinical development of a drug lead candidate against human parainfluenza virus – Exploratory pharmacokinetic, toxicity, and metabolic studies	TetraQ and Centre for Drug Candidate Optimisation
2020-21 (Round 2 - Screening)	A/Prof Ian Street	Children's Cancer Institute	Development of an assay system to identify CNS-penetrant derivatives of pre-existing drugs for brain cancer	ACRF Drug Discovery Centre
2020-21 (Round 2 - Screening)	Prof Klaus-Martin Schulte	Australian National University	Identifying therapeutics for the treatment of advanced BRCA2 breast cancer”	ANU Centre for Therapeutic Discovery
2020-21 (Round 2 - Screening)	Prof Mark Dawson	Peter MacCallum Cancer Centre	Identification of novel immune-checkpoint therapies to inhibit interaction between PD-L1 and CMTM6, a new regulator of anti-tumour immunity	Discovery Biology
2020-21 (Round 2 - Screening)	Dr Jess Tiffen	Centenary Institute	Identifying Epigenetic Drivers of Drug Resistant Melanoma	Discovery Biology
2020-21 (Round 2 - Screening)	A/Prof Ethan D. Goddard-Borger	WEHI	Developing fucosyltransferase inhibitors as treatments for rare leukaemia	Monash Fragment Platform
2020-21 (Round 2 - Screening)	Dr Ueli Nachbur	WEHI	Identification of small molecule binders to Deubiquitinases	Monash Fragment Platform
2020-21 (Round 2 - Screening)	Prof Frederic Hollande	University of Melbourne	Developing a combined small molecule and immune cell killing assay to identify new therapeutics in pancreatic cancer”	Victorian Centre for Functional Genomics
2020-21 (Round 2)	Dr Chengxue Helena Qin	Monash University	Next generation formyl peptide receptor 2 agonists to treat pulmonary hypertension	Australian Translational Medicinal Chemistry Facility
2020-21 (Round 2)	Dr Mitali Sarkar-Tyson	University of Western Australia	Advanced development of therapeutics against bacterial pathogens of biowarfare concern	Australian Translational Medicinal Chemistry Facility
2020-21 (Round 2)	A/Prof Daniel Thomas	University of Adelaide	Iterative design of selective Type II JAK2 Inhibitor for superior management of myelofibrosis	Australian Translational Medicinal Chemistry Facility
2020-21 (Round 2)	Dr Nadia Warner	Peter Doherty Institute for Infection and Immunity	Synthesis and development of targeted degraders of the hepatitis B virus (HBV) core proteins for HBV therapy	Australian Translational Medicinal Chemistry Facility
2020-21 (Round 2)	Dr Mark Devlin	Aculeus Therapeutics Pty Ltd	Systemically delivered small molecule STING agonists as next generation cancer immunotherapies	Centre for Drug Candidate Optimisation
2020-21 (Round 2)	Dr Paul Stupple	CTx/Monash University	In vivo and in vitro pharmacokinetic studies of novel therapeutics against blood cancers	Centre for Drug Candidate Optimisation
2020-21 (Round 2)	Dr Chris Langmead	Monash University	Development of biased agonists for schizophrenia	Centre for Drug Candidate Optimisation and Australian Translational Medicinal Chemistry Facility
2020-21 (Round 2)	Dr Pegah Varamini	University of Sydney	Development of novel therapeutics for targeted therapy of triple negative breast cancer	Centre for Integrated Preclinical Drug Development
2020-21 (Round 2)	Dr Julian Barden	Biosceptre Aust Pty Ltd	Development of novel cellular cancer therapeutics	National Biologics Facility NSW Node
2020-21 (Round 2)	A/Prof Ashley Buckle	Monash University	Development of novel anti-inflammatory biologics	National Biologics Facility Queensland Node
2020-21 (Round 2)	Prof Elizabeth Coulson	University of Queensland	Therapeutic antibody discovery to block neurotrophin receptor cleavage	National Biologics Facility Queensland Node
2021-22 (Round 1)	Prof Ian Smyth	Monash University	Inhibiting cyst formation in polycystic kidney disease with targeted protein degraders (TPDs)	Australian Translational Medicinal Chemistry Facility
2021-22 (Round 1)	A/Prof Nick Clemons	Peter MacCallum Cancer Centre	Synthesis of novel small molecule inhibitors of SLC7A11/XCT for mutant-p53 cancers	Australian Translational Medicinal Chemistry Facility
2021-22 (Round 1)	Dr Robert Feldman	COVID-19 Vaccine Corporation	Development of an mRNA cytotoxic T-cell COVID-19 vaccine	BASE Facility
2021-22 (Round 1)	Dr Willem Joost Lesterhuis	Telethon Kids Institute	Development of small molecule drugs in immuno-oncology	Centre for Drug Candidate Optimisation
2021-22 (Round 1)	A/Prof Jonathan S. Oakhill	St Vincent's Institute of Medical Research	Development of CaMKK2 inhibitors as new cancer therapies	Centre for Drug Candidate Optimisation
2021-22 (Round 1)	Dr Samantha South	Argenica Therapeutics Ltd	Neuroprotective efficacy of poly-argine-18 (R18) in a relapsing-remitting experimental autoimmune encephalomyelitis (RR-EAE) mouse model of multiple sclerosis (MS)	Centre for Integrated Preclinical Drug Development
2021-22 (Round 1)	Dr Ben Rollo	Monash University	Human high-throughput in-vitro phenotypic screening for new epilepsy drugs	Compounds Australia
2021-22 (Round 1)	Prof Sudha Rao	QIMR Berghofer	Identification of a small molecule inhibitor for therapeutic targeting of a novel nuclear methyltransferase in immunotherapy-resistant metastatic cancers	GRIDD Mass Spectrometry Screening
2021-22 (Round 1)	A/Prof Jenny Gunnersen	University of Melbourne	Screening for therapeutic antibodies to treat chronic pain	National Biologics Facility Queensland Node
2021-22 (Round 1)	Prof John Hooper	Mater Research Institute	Process development to optimise and characterise the conjugation process of DFO and monoclonal antibody 10D7	National Biologics Facility Victoria Node
2021-22 (Round 1)	Dr Nicholas Hunt	University of Sydney	Synthesis and characterisation of Ag2S quantum dots and conjugation to insulin at CSIRO	National Biologics Facility Victoria Node
2021-22 (Round 1)	Dr Chisha Teza Sikazwe	PathWest Laboratory Medicine WA	Development of recombinant MVEV and JEV NS1 antigen for the detection of JEV and MVEV antibody in serum	Protein Expression Facility
2021-22 (Round 1)	Prof Rajiv Khanna	QIMR Berghofer	The establishment of a repository of in vitro-expanded cytomegalovirus-specific T cells for the treatment of glioblastoma multiforme	Q-Gen Cell Therapeutics
2021-22 (Round 1)	Prof John EJ Rasko	Centenary Institute	Novel gene therapy platforms for hemophilia B	Vector and Genome Engineering Facility
2021-22 (Round 1)	Dr Gonzalo Perez-Siles	ANZAC Research Institute	Development of a high throughput screening platform of patient-derived iPSC motor neuron for enhancers of energy metabolism as a therapeutic intervention in axonal degeneration	Victor Chang Cardiac Research Institute
2021-22 (Round 1)	Dr Marie Besnier	University of Sydney	Treating the mitochondria to improve endothelial function of patients with coronary artery disease	Victor Chang Cardiac Research Institute
2021-22 (Round 1)	Dr Mitchell Lawrence	Monash University	New generation combination therapies for advanced prostate cancer	Victorian Centre for Functional Genomics
2021-22 (Round 2)	Prof Christopher Langmead	Monash Institute of Pharmaceutical Sciences	Development of novel agonists for schizophrenia	Australian Translational Medicinal Chemistry Facility
2021-22 (Round 2)	Prof Roland Stocker	Heart Research Institute	Synthesis of a novel PET probe to detect plaque activity for the identification of high-risk atherosclerosis	Australian Translational Medicinal Chemistry Facility
2021-22 (Round 2)	Dr Thomas Theodor Tapmeier	Monash University	NPSR1 Antagonist in Endometriosis	Australian Translational Medicinal Chemistry Facility
2021-22 (Round 2)	Prof Ian Smyth	Monash University	Pharmacokinetic Assessments and optimisation of a new therapy for PKD	Australian Translational Medicinal Chemistry Facility and Centre for Drug Candidate Optimisation
2021-22 (Round 2)	A/Prof Ethan D. Goddard-Borger	Walter and Eliza Hall Institute of Medical Research	Development of anthelmintics with a novel mode of action	Centre for Drug Candidate Optimisation
2021-22 (Round 2)	Dr William Thomas Jorgensen	Psylo Pty Ltd	Pre-clinical development of novel serotonergic agents for therapeutic applications in mental illness	Centre for Drug Candidate Optimisation
2021-22 (Round 2)	Dr Sohinee Sarkar	Murdoch Children's Research Institute	A new treatment for the cystic fibrosis superbug, Mycobacteroides abscessus	Compounds Australia
2021-22 (Round 2)	Dr Nicole Van Bergen	Murdoch Children’s Research Institute	Utilising high-throughput drug screening for mitochondrial metabolite repair disorders	Compounds Australia
2021-22 (Round 2)	Dr Katherine Locock	CSIRO	Accelerated antibiotic discovery through high-throughput	Compounds Australia and Community for Open Antimicrobial Drug Discovery
2021-22 (Round 2)	A/Prof Rebecca Lim	Prescient Therapeutics	Preclinical toxicity studies for OmniCAR-enabled targeting ligands	National Biologics Facility Queensland Node
2021-22 (Round 2)	Prof Kristen Radford	Mater Research Institute	Development of human CLEC9A antibodies as cancer vaccines	National Biologics Facility Queensland Node
2021-22 (Round 2)	Dr Sarah Jones	Monash University	A novel Glucocorticoid (GC) mimic for the treatment of inflammatory and autoimmune diseases	National Biologics Facility Victoria Node
2021-22 (Round 2)	A/Prof Rebecca Lim	Hudson Institute of Medical Research	Phase II Amnion Cell Therapy in Ischemic Stroke	Q-Gen Cell Therapeutics
2021-22 (Round 2)	Prof Timothy Stinear	University of Melbourne	A high-throughput screening campaign to find inhibitors of intracellular multi-drug resistant Staphylococcus aureus	Victorian Centre for Functional Genomics
2021-22 (Round 2)	A/Prof Kara Britt	Peter MacCallum Cancer Centre	Identify drugs that selectively inhibit oestrogen receptor positive luminal progenitor activity	Victorian Centre for Functional Genomics
2022-23 (Round 1)	Prof Philip Board	Omega-One Therapeutics Pty. Ltd.	Developing Glutathione transferase Omega 1 inhibitors as anti-inflammatory therapeutics	Australian Translational Medicinal Chemistry Facility
2022-23 (Round 1)	Prof Enzo Porrello	Murdoch Children's Research Institute	Developing next generation cardio-regenerative therapeutics to treat systolic heart failure	Australian Translational Medicinal Chemistry Facility
2022-23 (Round 1)	Dr Richard Foitzik	Oncology One Pty Ltd	ADME investigation into methyltransferase inhibitor candidates	Centre for Drug Candidate Optimisation
2022-23 (Round 1)	Ms Filippa Shub	Inosi Therapeutics	IRAP inhibitor lead optimisation	Centre for Drug Candidate Optimisation
2022-23 (Round 1)	Prof Mark von Itzstein	Institute for Glycomics, Griffith University	Development of drug candidates against drug resistant bacteria	Centre for Drug Candidate Optimisation
2022-23 (Round 1)	Prof Brian Gabrielli	Mater Research Institute	Screen for compounds synthetically lethal with defective RB and p53	Discovery Biology Griffith
2022-23 (Round 1)	Mr Robert Batchelor	Nutromics Pty Ltd	Surface plasmon resonance-based screening of DNA aptamers targeted to small molecule drugs	Monash Fragment Platform
2022-23 (Round 1)	Dr Jacek Kwiatkowski	Queensland Emory Drug Discovery Initiative	Identification of Inhibitors of a Key Necroptotic Protein Through Fragment Screening	Monash Fragment Platform
2022-23 (Round 1)	Prof Alastair Stewart	University of Melbourne	Discovery of selective inhibitors for fibrosis	Monash Fragment Platform
2022-23 (Round 1)	Mr Paul Fahey	Vaxxas Pty. Ltd.	Enhanced skin delivery of vaccines by manipulating surface interactions on High Density Micro Array Patches (HD-MAP’s).	National Biologics Facility Victoria Node
2022-23 (Round 1)	A/Prof Daniel Thomas	University of Adelaide	Anti-mutant CALR Antibody Preparation for Clinical Manufacture for Patients with Myelofibrosis	National Biologics Facility Queensland Node
2022-23 (Round 1)	Dr Graham Heery	Starpharma Pty Ltd	Production of a HER2 binding nanobody for the assembly of targeted novel dendrimer therapeutics for breast and gastric cancer	Protein Expression Facility
2022-23 (Round 1)	Prof James St John	Griffith University	Spinal Injury Project: pilot-scale GMP production and validation of clinically compliant nerve bridges	Q-Gen Cell Therapeutics
2022-23 (Round 1)	Dr Steve Dingwall	Australian Institute for Bioengineering and Nanotechnology	Generation of Induced Pluripotent Stem Cell Master and Working Cell Banks for a Phase 1 Clinical Trial for the Treatment of Heart Failure	Q-Gen Cell Therapeutics
2022-23 (Round 1)	Prof Andrew Elefanty	Murdoch Children's Research Institute	Building a better leukaemia – Modeling paediatric acute myeloid leukaemia in pluripotent stem cells	Stafford Fox Disease Modelling Facility
2022-23 (Round 1)	A/Prof Silvia Velasco	Murdoch Children's Research Institute	Development of a platform for the automated generation and high-throughput drug screening of brain organoids	Stafford Fox Disease Modelling Facility
2022-23 (Round 1)	Prof Robyn Jamieson	Children's Medical Research Institute	Long-term AAV-mediated genetic rescue of photoreceptors in retinitis pigmentosa	Sydney Cell and Gene Therapies
2022-23 (Round 1)	A/Prof James Chong	Westmead Institute for Medical Research	Process development for the preparation and delivery of induced pluripotent stem cell derived cardiomyocytes for end stage heart failure.	Sydney Cell and Gene Therapy
2022-23 (Round 1)	A/Prof Elaine Sanij	St Vincent's Institute of Medical Research	Development of new cancer therapeutics targeting the nucleoli	Victorian Centre for Functional Genomics
2022-23 (Round 2)	Dr Balaji Somasundaram	Denteric Pty Ltd	Enabling translation of a therapeutic vaccine candidate against Porphyromonas gingivalis	National Biologics Facility Queensland Node
2022-23 (Round 2)	Ms Reema Bajaj	Burnet Institute	Engineering IgG-like ACE2 antivirals against future pathogenic coronavirus events	National Biologics Facility Queensland Node
2022-23 (Round 2)	Prof Fabienne Mackay	QIMR Berghofer Medical Research Institute	Large-scale production of a TACI-targeting antibody to test its therapeutic efficacy in a preclinical model of chronic lymphocytic leukaemia.	Protein Expression Facility
2022-23 (Round 2)	Dr Evan Wong	Lions Eye Institute, Sir Charles Gairdner Hospital and Royal Perth Hospital	Validation of GMP-compliant manufacture of corneal endothelial cells for intraocular injection as an alternative to corneal transplantation	Cell & Tissue Therapies WA
2022-23 (Round 2)	A/Prof Joshua Ooi	Monash University	Manufacture of autologous T regulatory cells modified ex vivo to express T cell receptors for autoimmune disease	Centre of Excellence in Cellular Immunotherapy
2022-23 (Round 2)	A/Prof David Ian Roper FRSC	University of Warwick,UK	Drug discovery for bacterial glycosyltransferases to combat AMR using the Monash Fragment Platform (MFP) screening facility	Monash Fragment Platform
2022-23 (Round 2)	A/Prof Ann Kwan	University of Sydney	Targeting FtsY for a new class of antibiotics	Monash Fragment Platform
2022-23 (Round 2)	Dr Chengxue Helena Qin	Monash University	Novel disease-modifying approach to treat pulmonary hypertension	Australian Translational Medicinal Chemistry Facility
2022-23 (Round 2)	Dr Steven Suchting	Emenda Therapeutics Australia Pty Ltd	Development of SRPK1 kinase inhibitors for osteoarthritis pain	Centre for Drug Candidate Optimisation
2022-23 (Round 2)	Dr William Thomas Jorgensen	Psylo Pty Ltd and the University of New South Wales	Understanding the key electronic and structural features for optimal brain penetration of a subset of our novel serotonergic agonists for CNS therapeutic applications	Centre for Drug Candidate Optimisation
COVID-19 (2020)	Dr Arun Konagurthu	Monash University	Modelling, synthesis and testing of potential agents against COVID-19 main protease	Australian Translational Medicinal Chemistry Facility
COVID-19 (2020)	Dr Charles Bailey	Centenary Institute	Monitoring the therapeutic efficacy of BD-218, a human neutralising monoclonal antibody against SARS-CoV-2, in COVID-19 patients using Nanostring gene expression analysis	Cell & Molecular Therapies, Royal Prince Alfred Hospital
COVID-19 (2020)	Prof Bevyn Jarrott	Vailima Peninsula Pty Ltd	Pre-clinical development of a novel, patented small molecule to treat COVID-19 respiratory injury	Centre for Drug Candidate Optimisation
COVID-19 (2020)	Dr Richard Angell	University College London	Using fragment-based drug discovery to identify small molecule inhibitors of SARS-CoV-2 (COVID-19) RNA-dependent RNA polymerase (RdRp) and future starting points for other Coronaviruses	Monash Fragment Platform
COVID-19 (2020)	Prof John Hayball	Sementis Ltd/UniSA	Large-scale manufacture of the Sementis Copenhagen Vector (SCV) COVID-19 vaccine	National Biologics Facility Victoria Node
COVID-19 (2020)	Prof Terrance Johns	Telethon Kids Institute	Discovery of antibodies to the furin cleavage site of SARS-CoV-2 Spike Glycoprotein	National Biologics Facility Queensland Node
COVID-19 (2020)	A/Prof Severine Navarro	QIMR Berghofer Medical Research Institute	Prevention of COVID-19-induced hyperinflammatory syndrome with the immunomodulatory protein AIP-2”	National Biologics Facility Queensland Node
COVID-19 (2020)	Dr Keith Dredge	Zucero Therapeutics Ltd	Analytical and bioanalytical development of pixatimod (ZU545/PG545)- a clinical candidate for cancer with anti-viral and anti-inflammatory properties - to support clinical testing for Covid-19”	TetraQ
COVID-19 (2020)	Dr Cameron Stewart	Australian Centre for Disease Prevention (ACDP), CSIRO	Defining the role of host microRNAs in COVID-19”	Victorian Centre for Functional Genomics
2022-23 Technical Feasibility Assessments	A/Prof Anthony Kicic	Telethon Kids Institute	Making bacteriophage therapy a reality: Implementation of a novel treatment pipeline to treat antimicrobial-resistant infections.	Cell & Tissue Therapies WA
2022-23 Technical Feasibility Assessments	A/Prof Joshua Ooi	Monash University	Manufacture of autologous T regulatory cells modified ex vivo to express T cell receptors for autoimmune disease	Centre of Excellence in Cellular Immunotherapy
2022-23 Technical Feasibility Assessments	Prof Enzo Porrello	Murdoch Childrens Research Institute	Evaluating technical feasibility of cGMP production of bioengineered heart tissue to treat heart failure in congenital heart disease	Centre of Excellence in Cellular Immunotherapy
2022-23 Technical Feasibility Assessments	Dr Rhonda Taylor	The University of Western Australia (UWA)	Allele-selective CRISPR deletion as a therapy for ACTA1 congenital myopathy	Cell & Tissue Therapies WA
2022-23 Technical Feasibility Assessments	Dr Evan Wong	Royal Perth Hospital	Validation of GMP-compliant manufacture of corneal endothelial cells for injection	Cell & Tissue Therapies WA
2023-24 (Round 1)	Mr Miguel Aguirre	University of Queensland	Development of a vaccine to prevent Group A Streptococcus pharyngeal infection	Protein Expression Facility
2023-24 (Round 1)	Dr Natalie Borg	RMIT University	Development of novel agents targeting severe viral infections	CSIRO Biomedical Manufacturing
2023-24 (Round 1)	Prof Rachel Codd	The University of Sydney	Efficacy and toxicity measures of a new class of iron chelator	Centre for Drug Candidate Optimisation
2023-24 (Round 1)	Dr Jonathan Danon	The University of Sydney	Innovative Molecules for Imaging Neuroinflammation	Centre for Drug Candidate Optimisation
2023-24 (Round 1)	A/Prof Garron Dodd	The University of Melbourne	Identifying New Targets to Treat Metabolic Disease	Victorian Centre for Functional Genomics
2023-24 (Round 1)	Dr Serena Duchi	University of Melbourne	Developing a GMP Compliant Adipose Derived Stem Cell Manufacturing Process for Cartilage Based Stem Cell Therapies	Cell & Molecular Therapies
2023-24 (Round 1)	Prof Tom Gonda	University of South Australia	Structure-Activity Analysis and Optimisation of Potential MYB-p300 Inhibitors	Australian Translational Medicinal Chemistry Facility
2023-24 (Round 1)	Prof Shane T Grey	Garvan Institute of Medical Research	Development of a novel anti inflammatory gene therapy for type 1 diabetes	Sydney Cell and Gene Therapy
2023-24 (Round 1)	Dr David Jacques	University of New South Wales	Developing anti-capsid therapeutics for HTLV-1	Monash Fragment Platform
2023-24 (Round 1)	Dr Sarah Jones	Monash University	Fragment screen for E3 ligase inhibitors	Monash Fragment Platform
2023-24 (Round 1)	Dr Aggie Susanti Lawer	University of Sydney	Developing Precision Covalent Therapeutics to Target Protein Disulfide Isomerase A6: A Novel and Safer Strategy Against Acute Ischaemic Stroke	GRIDD Mass Spectrometry Screening and Compounds Australia
2023-24 (Round 1)	Dr Willem Joost Lesterhuis	Telethon Kids Institute	Small molecule drugs in immuno-oncology	Centre for Drug Candidate Optimisation
2023-24 (Round 1)	Dr Steven Petratos	Monash University	Development of Integrin αVβ3 Agonists to Promote Remyelination in Multiple Sclerosis	Australian Translational Medicinal Chemistry Facility
2023-24 (Round 1)	A/Prof Matthew Piggott	University of Western Australia and Emyria Ltd	Hit to lead optimisation of novel drug candidates targeting mental health and neurodegenerative diseases.	Centre for Drug Candidate Optimisation
2023-24 (Round 1)	Dr Sohinee Sarkar	Murdoch Children’s Research Institute	A stem cell powered drug discovery pipeline for non-tuberculous mycobacteria	Stem Cell Disease Modelling & Drug Screening Facility (MCRI)
2023-24 (Round 1)	A/Prof Ian Street	Children's Cancer Institute	Developing METTL5 Inhibitors for the treatment of paediatric neuroblastoma and adult solid tumours	Australian Translational Medicinal Chemistry Facility and Centre for Drug Candidate Optimisation
2023-24 (Round 1)	Dr Thomas Tapmeier	Monash University	Peripherally Restricted NPSR1 Antagonist in Endometriosis	Australian Translational Medicinal Chemistry Facility and Centre for Drug Candidate Optimisation
2023-24 (Round 1)	Dr Pegah Varamini	University of Sydney	Development of new nano-platforms for the treatment of triple negative breast cancer (TNBC).	Centre for Integrated Preclinical Drug Development
2023-24 (Round 1)	Dr Rosalind Wilson	Carpe Vitae Pharmaceuticals	Development of a novel drug targeting age-related diseases	Centre for Drug Candidate Optimisation
2023-24 (Round 1)	A/Prof Andrew Wise	Bionics Institute	Optimisation of a therapeutic neurotrophin molecule to enable evaluation in a first in human clinical trial	CSIRO Biomedical Manufacturing
2023-24 Technical Feasibility Assessments (Round 1)	Dr Anai Gonzalez Cordero	Children’s Medical Research Institute	Developing an ‘allogeneic stem cell-derived photoreceptor cell product’ compatible with good manufacturing practice (GMP) conditions.	Sydney Cell and Gene Therapy (Westmead Precinct)
2023-24 Technical Feasibility Assessments (Round 1)	Prof David Gottlieb	Western Sydney Local Health District, University of Sydney	Commercial scale up of CMV and EBV specific T-cell manufacturing	Centre of Excellence in Cellular Immunotherapy (Peter MacCallum Cancer Centre)
2023-24 Technical Feasibility Assessments (Round 1)	Mr David Thomas Kneen	Celleo Biotech Pty Ltd	Automated aseptic manufacture of serum eye drops for patients suffering dry eye conditions	Cell & Tissue Therapies WA (Royal Perth Hospital)
2023-24 Technical Feasibility Assessments (Round 1)	Dr Saparna Pai	James Cook University	Retrieving short-term memories for tuberculosis treatment	Q-Gen Cell Therapeutics (QIMR Berghofer)
2023-24 Technical Feasibility Assessments (Round 1)	A/Prof Jason Waithman	University of Western Australia	Improving adoptive cell therapy protocols through transcriptional rewiring of T cells	Cell & Tissue Therapies WA (Royal Perth Hospital)
2023-24 Technical Feasibility Assessments (Round 1)	Prof Majid Ebrahimi Warkiani	SMART MCs Pty Ltd	Biodegradable Microcarriers for Therapeutic Stem Cells: A Feasibility Analysis for Large-Scale Production	Cell & Tissue Therapies WA (Royal Perth Hospital)
2023-24 (Round 2)	A/Prof Greg Arndt	Children's Cancer Institute	Hit identification using DEL for the development of small molecule targeted treatment of osteosarcomas	Monash Fragment Platform
2023-24 (Round 2)	Dr Sofia Burgener	University of Queensland	Caspase-1 inhibitors for the treatment of inflammatory disease	Compounds Australia, Queensland Emory Drug Discovery Initiative and Mass Spectrometry Screening Platform
2023-24 (Round 2)	A/Prof Antoine de Weck	Children's Cancer Institute	The druggable transcriptome: Small Molecules inducing Reading Frame Stops (SMIRFS)	ACRF Drug Discovery Centre for Childhood Cancer
2023-24 (Round 2)	Dr Natalie Diepenhorst	Monash University	Lead discovery for the orphan GPCR, GPR88	Monash Fragment Platform
2023-24 (Round 2)	Dr Rabina Giri	Mater Research Institute	Microbiome derived IBD small molecule	Queensland Emory Drug Discovery Initiative
2023-24 (Round 2)	Prof Mohammed Akhter Hossain	Florey Institute of Neuroscience and Mental Health	Novel brain peptide receptor analgesics: Accelerated target validation and pre-clinical testing of RXFP3 activators	Centre for Integrated Preclinical Drug Development
2023-24 (Round 2)	Dr Adam Johnson	Skin2Neuron	Development of automated manufacture of hair follicle-derived neuroprecursors for GLP-Tox IND-enabling studies	Biologics Innovation Facility
2023-24 (Round 2)	Scientia A/Prof Nadeem Kaakoush	University of New South Wales	Discovery of novel therapeutic compounds targeting the microbiome-immune axis in ulcerative colitis	ANU Centre for Therapeutic Discovery
2023-24 (Round 2)	A/Prof Charlene Kahler	University of Western Australia	Breaking ceftriaxone resistance in Neisseria gonorrhoeae using an inhibitor of lipid A phosphethanolamine transferase (EptA)	Monash Fragment Platform
2023-24 (Round 2)	Dr Hannah Kelly	Australian National University	Improving mRNA vaccines with precision vaccinology	UNSW RNA Institute
2023-24 (Round 2)	Prof Chris Langmead	Phrenix Therapeutics Pty Ltd	Pre-candidate selection for novel schizophrenia therapeutics	Centre for Drug Candidate Optimisation
2023-24 (Round 2)	Dr Makutiro Masavuli	Basil Hetzel Institute (BHI) for Translational Health Research	mRNA vaccine for HCV	BASE Facility
2023-24 (Round 2)	Dr Michael Nafisinia	Westmead institute for Medical Research	Enhancing Therapeutic Efficacy: Pioneering Large-Scale Drug Pipeline Development and Testing on PKU Patients' iPSC-Derived Hepatocytes	ACRF Drug Discovery Centre for Childhood Cancer
2023-24 (Round 2)	Dr Rhys Parry	University of Queensland	Self-amplifying RNAs with modified NTPs: a next-generation vaccine and therapeutic platform.	BASE Facility
2023-24 (Round 2)	Dr Louise Robertson	University of Adelaide	Next-generation CRISPR therapeutics for autosomal dominant retinitis pigmentosa	Vector and Genome Engineering Facility and South Australia Genome Editing Facility
2023-24 (Round 2)	A/Prof Danielle Stanisic	Griffith University	Manufacturability assessment of a whole parasite malaria vaccine	CSIRO Biomedical Manufacturing
2023-24 (Round 2)	Dr Ruth Thornton	Telethon Kids Institute	Blitz-OM- development of a slow-release anti-biofilm treatment to prevent the need for recurrent grommet surgery	CSIRO Biomedical Manufacturing
2023-24 (Round 2)	A/Prof Kathryn Fay Tonissen	Griffith University	Characterisation of covalent binders for a potential new drug target in oncology, Carbonic Anhydrase 3	Compounds Australia and Mass Spectrometry Screening Platform
2023-24 (Round 2)	Dr Rohan Volpe	Walter and Eliza Hall Institute of Medical Research	Pharmacokinetic profiling of two novel antiviral coronavirus protease inhibitors towards clinical application for COVID-19 and beyond.	Centre for Drug Candidate Optimisation
2023-24 (Round 2)	Prof Stephanie Watson	University of Sydney	Transforming corneal stem cell-based therapies with innovative bioengineered technologies	CSIRO Biomedical Manufacturing
2023-24 (Round 2)	Dr Lucia Florencia Zacchi	University of Queensland	Characterisation of novel antibodies for the treatment of neuropathic pain	National Biologics Facility
2023-24 (Round 2)	Michael Grant	Q-Sera Pty Ltd	RAPClot bioassay validation and optimisation	CSIRO Biomedical Manufacturing
2023-24 Technical Feasibility Assessments (Round 2)	Dr Yvette Wooff	Australian National University	Red blood cell-extracellular vesicles to treat retinal degenerative diseases.	Centre of Excellence in Cellular Immunotherapy
2023-24 Technical Feasibility Assessments (Round 2)	Dr Sarah Sutherland	Chris O’Brien Lifehouse	Exploring the Feasibility of Tumour Infiltrating Lymphocyte (TIL) Therapy in Appendiceal Cancer	Cell & Molecular Therapies
2024-25 (Rounds 1)	Prof Katherine Andrews	Griffith University	Screening chemically diverse compounds that represent untested chemical space for activity against Plasmodium malaria parasites	National Drug Discovery Centre
2024-25 (Rounds 1)	Dr Sheng Yu Ang	Neuromedicines Discovery Centre (NDC), Monash University	Potent and selective non-hallucinogenic serotonin 2A receptor agonists for the treatment of severe mental health disorders	Australian Translational Medicinal Chemistry Facility
2024-25 (Rounds 1)	Dr Stephan Brouwer	Institute for Molecular Bioscience, The University of Queensland	Development of an optimised vaccine formulation to prevent Group A Streptococcus infection	Protein Expression Facility
2024-25 (Rounds 1)	Dr Rosemary Cater	Institute for Molecular Bioscience, University of Queensland (UQ)	FLVCR2 inhibition for the treatment of glioblastoma	Compounds Australia, Qld Emory Drug Discovery Initiative and IBG-Nathan Mass Spec Facility
2024-25 (Rounds 1)	Prof Peter Currie	Australian Regenerative Medicine Institute, Monash University	Development of NAMPT-cif Fc fusion for treatment of muscle disease	CSIRO Biomedical Manufacturing
2024-25 (Rounds 1)	Prof Bryan Day	Group Leader, Sid Faithfull Brain Cancer Laboratory, QIMR Berghofer Medical Research Institute	Novel Eph Receptor Antibody Drug Conjugate Therapy Development for the Treatment of Paediatric Brain Cancer	National Biologics Facility
2024-25 (Rounds 1)	Dr Bijay Dhungel	Centre for Rare Diseases & Gene Therapy, Centenary Institute, The University of Sydney	Muscle-targeted adeno-associated viruses for safer gene therapy	Vector and Genome Engineering Facility (CMRI)
2024-25 (Rounds 1)	Dr Aude Dorison	Murdoch Children’s Research Institute	Screening for new treatments for glomerular disease with a new stem cell reporter line	"Stem Cell Disease Modelling & Drug Screening Facility Induced Pluripotent Stem Cell Derivation & CRISPR Gene Editing Facility (MCRI)"
2024-25 (Rounds 1)	Dr Frances Evesson	The University of Sydney, Children’s Medical Research Institute and Sydney Children’s Hospitals Network	Therapeutic possibilities for PYROXD1 myopathy	mRNA CORE
2024-25 (Rounds 1)	A/ Prof Richard Gordon	Translational Research Institute - Queensland University of Technology	Screening and validation of novel therapeutic agents for inflammation resolution and neuroprotection in Parkinson's disease	Compounds Australia
2024-25 (Rounds 1)	Dr Kavitha Gowrishankar	Kids Research Institute, Children’s Hospital Westmead, Sydney Children’s Hospital Network	EphA2 Chimeric Antigen Receptor (CAR) T cell Therapy for Children with Bone Tumours: A Phase I Clinical Trial	Sydney Cell and Gene Therapy (Westmead Precinct)
2024-25 (Rounds 1)	A/ Prof Zi (Sophia) Gu	School of Chemical Engineering, University of New South Wales	Development of a mRNA nanoparticle formulation for low back pain treatment	RNA Institute
2024-25 (Rounds 1)	Mrs Harsha Gupta	Cynata Therapeutics Limited	Development of cryopreserved wound patches with stem cells ready for thawing at point of care	Cell & Tissue Therapies WA (Royal Perth Hospital)
2024-25 (Rounds 1)	A/ Prof Willem Joost Lesterhuis	The Kids Research Institute Australia	Lead-to-candidate optimisation of a small molecule oncology drug	Centre for Drug Candidate Optimisation
2024-25 (Rounds 1)	Dr Brian Liddicoat	exteRNA	Targeting novel RNA biology in cancer	Monash Fragment Platform
2024-25 (Rounds 1)	Dr Rebecca Nisbet	The Florey Institute of Neuroscience and Mental Health	Development of an active immunotherapy for Alzheimer's disease	mRNA CORE
2024-25 (Rounds 1)	Dr Ralph Patrick	Institute for Molecular Bioscience, The University of Queensland	Synthesis and Characterization of Transcription Factor Inhibitors for Therapeutic Interventions in Age-Related Conditions	Centre for Drug Candidate Optimisation and Qld Emory Drug Discovery Initiative
2024-25 (Rounds 1)	Prof Damian F.J. Purcell	The University of Melbourne	RNA Powered Antiviral Antibodies	National Biologics Facility
2024-25 (Rounds 1)	Dr Chengxue Helena Qin	Monash University	Novel disease-modifying approach to treat pulmonary hypertension	Australian Translational Medicinal Chemistry Facility
2024-25 (Rounds 1)	Dr Ioanna Savvidou	Monash university	Development of endothelial targeted-CD39 as a novel treatment for micro circulatory thrombosis in stroke and global brain ischaemia.	Biologics Innovation Facility
2024-25 (Rounds 1)	Dr Nicole van Bergen	Murdoch Children’s Research Institute	High-throughput drug screening for paediatric epilepsy due to pathogenic variants in CDKL5	Compounds Australia and Stem Cell Disease Modelling & Drug Screening Facility
2024-25 (Rounds 1)	A/ Prof Nicholas Veldhuis	Monash Institute of Pharmaceutical Sciences, Monash University, Parkville	Assessing efficacy of new generation analgesic nanoparticles for osteoarthritic pain	Centre for Integrated Preclinical Drug Development
2024-25 (Rounds 1)	Dr Mai Ngoc Vu	University of Melbourne	Harnessing mRNA Lipid Nanoparticles For Efficient Delivery Of Influenza Monoclonal Antibody Therapeutics	BASE Facility
2024-25 (Rounds 1)	Prof Carl Walkley	Hudson Institute of Medical Research and Monash University	Developing new therapies to treat ADAR1 mutant disease.	ANU Centre for Therapeutic Discovery
2024-25 (Rounds 1)	A/ Prof Michelle Wykes	QIMR Berghofer/ Fovero Therapeutics	Novel therapy for cancer	CSIRO Biomedical Manufacturing
2024-25 (Rounds 1)	Dr Dannel Yeo	Centenary Institute	Tumour infiltrating lymphocyte therapy for appendiceal cancer	Cell & Molecular Therapies (Royal Prince Alfred Hospital)
2024-25 Technical Feasibility Assessments (Round 1)	A/ Prof Elizabeth Ng	Murdoch Children’s Research Institute	Autologous haematopoietic stem cells, moving transplantation into the 21st century	Cell Therapies

Generated by wpDataTables

Search and sort the table below for details on projects supported by TIA’s Pipeline Accelerator scheme.

TIA voucher outcomes

Contact us